REFERENCE
Earnshaw SR, Moride Y, Rochon S.Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clinical Therapeutics 29: 2096-2106, No. 9, Sep 2007
Rights and permissions
About this article
Cite this article
Pegaptanib eyes up the competition in AMD. Pharmacoecon. Outcomes News 543, 9 (2007). https://doi.org/10.2165/00151234-200705430-00024
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705430-00024